AORT

Artivion, Inc.

Cryolife Inc is engaged in medical device manufacturing and distribution and in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It has two segments: Medical Devices and Preservation Services.

Artivion, Inc. (AORT) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Momentum (C-). The rating has held at C+ for 6 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
C+
Factor Score 2.7 / 5.0
Growth
C+
Factor Score 2.6 / 5.0
Profitability
B
Factor Score 3.2 / 5.0
Momentum
C-
Factor Score 1.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 35.5
EV / EBITDA 20.1
Rev Growth YoY 9.2%
Gross Margin 63.3%
Price Return 3M -36.1%
Price Return 12M -59.5%
Catalyst Signal 0.00
Market Cap $901.1M
TTM Revenue $481.9M
Price / Sales 1.9
ROE -4.0%

Historical Factor Score Progression

Held C+ for 6 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.7) C+ (2.6) B (3.2) C- (1.9) C+ (2.6) C+ (2.6)
2026-11-10 C+ (2.5) C (2.4) B (3.2) C- (2.0) C+ (2.6) C+ (2.6)
2026-11-03 C+ (2.7) B- (3.0) B (3.2) C- (2.0) C+ (2.7) C+ (2.7)
2026-10-27 C+ (2.7) B- (3.0) B (3.2) D+ (1.7) C+ (2.6) C+ (2.7)
2026-10-20 C+ (2.8) B- (3.0) B (3.2) C- (1.9) C+ (2.6) C+ (2.7)
Page 1 of 8
…